Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline

Minerva Neurosciences ( (NERV) ) just unveiled an update.

Minerva Neurosciences, Inc. announced that its 2026 annual meeting of stockholders is expected to be held on June 3, 2026, a date set more than 30 days before the one-year anniversary of its 2025 annual meeting, and has therefore adjusted its timeline for shareholder participation accordingly. Stockholders must submit notices for business or director nominations by April 21, 2026, and proposals for inclusion in the company’s proxy materials by April 16, 2026, aligning governance and disclosure processes with its bylaws and securities regulations and clarifying deadlines for investors seeking to influence the meeting’s agenda.

The most recent analyst rating on (NERV) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.

Spark’s Take on NERV Stock

According to Spark, TipRanks’ AI Analyst, NERV is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses, heavy cash burn, and negative equity). Technicals also point to near-term weakness (negative MACD and price below key short-term averages). Positive corporate updates around Phase 3 planning and leadership strengthening provide some support, but do not offset the financial risk profile.

To see Spark’s full report on NERV stock, click here.

More about Minerva Neurosciences

Minerva Neurosciences, Inc. operates in the biopharmaceutical industry, focusing on the development of therapies for central nervous system disorders. The company targets neurological and psychiatric conditions, aiming to address unmet medical needs in these specialized patient populations and associated healthcare markets.

Average Trading Volume: 218,601

Technical Sentiment Signal: Hold

Current Market Cap: $228.5M

For an in-depth examination of NERV stock, go to TipRanks’ Overview page.